Evidence map›Paper›PMID 40596677›Full record

ArticleScientific reports2025

Risk factors for multidrug resistant and carbapenem resistant Pseudomonas aeruginosa bloodstream infections among inpatients in Central and East China.

Shuzhen Xiao, Deyong Zhu, Xianghui Liang, Lizhong Han, Shengyuan Zhao

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Observational
  2. Article
  3. A broad-host-range inhalable phage cocktail for treatment of multidrug-resistantFrontiers in cellular and infection microbiology · 2026
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shuzhen Xiao *Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Deyong Zhu *Department of Laboratory Medicine, The People's Hospital of Wenshan Prefecture, The Affiliated Hospital of Kunming University of Science and Technology, Wenshan, Yunnan, China.
Xianghui LiangDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Lizhong HanDepartment of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shengyuan ZhaoDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan, China. shengyuanzhao@csu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bloodstream infections (BSIs) caused by multidrug resistant Pseudomonas aeruginosa (MDRPA) and carbapenem resistant Pseudomonas aeruginosa (CRPA) accounted for high morbidity and mortality. This retrospective cohort study aimed to determine risk factors for MDRPA and CRPA BSIs by examining both clinical and laboratory data of inpatients with MDRPA and CRPA BSIs at two tertiary care hospitals in 2017-2021. Generalized linear mixed models were used to identify risk factors for MDRPA and CRPA BSIs. Factors significantly associated with both MDRPA BSIs and CRPA BSIs included central venous catheter, invasive ventilation including duration of use, urinary catheterization, gastric tube insertion, vancomycin use including quantity of usage, imipenem use including quantity of usage, and tigecycline use. Respiratory infection [adjusted odds ratio (aOR) 2.10, 95% confidence interval (95% CI) 1.00-4.42; P = 0.049] was identified as an independent risk factor for MDRPA BSIs. For CRPA BSIs, independent risk factors included the use of invasive ventilation [aOR 2.82, 95% CI 1.36-5.84; P = 0.005] and a history of tigecycline use [aOR 3.34, 95% CI 1.16-9.58; P = 0.025]. Conversely, circulatory system diseases [aOR 0.41, 95% CI 0.22-0.77; P = 0.006] and quantity of piperacillin-tazobactam use [aOR 0.83, 95% CI 0.72-0.96; P = 0.013] were identified as independent protective factors for CRPA BSIs. Inpatients with respiratory infection, invasive ventilation and a history of tigecycline use are at higher risk of MDRPA and CRPA BSIs. More prudent clinical interventions and antimicrobial therapy should be implemented to inpatients with these factors to prevent and control MDRPA and CRPA BSIs.

Indexed as

BacteremiaCarbapenemsDrug Resistance, Multiple, BacterialPseudomonas aeruginosaPseudomonas InfectionsAdultAgedAnti-Bacterial AgentsChinaFemaleHumansInpatientsMaleMiddle AgedRetrospective StudiesRisk FactorsAnti-Bacterial AgentsCarbapenemsBloodstream infectionsCarbapenem resistanceMultidrug resistancePseudomonas aeruginosaRisk factors

Identifiers

PMID40596677
PMCPMC12216560

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.